Ojer Pharma

ojerpharma.com ↗ ·Pamplona ·Seed

Ojer Pharma (Laboratorios Ojer Pharma S.L.) is a Pamplona-based biopharmaceutical company that researches, develops and markets innovative dermatological products for both human and veterinary use, spanning prescription drugs, OTC products, medical devices and cosmetics. Its core technology is a proprietary transparent bioadhesive gel delivery platform that acts as a sustained-release matrix for dermatological actives, improving efficacy while reducing toxicity. Founded in 2005 as a spin-off of the University of Navarra (promoted by FUNA), it has raised roughly €7M across successive capital increases, sells across five continents via partners, and recently obtained marketing authorization for Rhinoheal in Korea with QL Pharma.

Founded

2005

Founders

Total funds raised

€5M

SectorsPharmaceuticals, Dermatology, Biotech, Medical Devices, Animal Health, Cosmetics Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Carlos González Ojer

Founder, CEO & Chairman of the Board

Global models 5

Arcutis Biotherapeutics

United States · www.arcutis.com ↗

A dermatology-focused biopharma that develops and sells its own topical prescription treatments, putting known actives into better topical formulations, close to Ojer's approach.

~$225MComparable

MC2 Therapeutics

Denmark · www.mc2therapeutics.com ↗

A European dermatology company built on a proprietary topical formulation platform (PAD Technology) that improves how actives are delivered and tolerated on the skin, very close to Ojer's bioadhesive-gel platform.

~$150MComparable

Dermira

United States · www.dermira.com ↗

A venture-backed dermatology biopharma that developed and sold its own medical-dermatology products, including topical ones, before Eli Lilly bought it; the same develop-and-market model Ojer runs.

~$110MComparable

Novan

United States · www.novan.com ↗

A dermatology company whose core asset was a proprietary topical nitric-oxide release platform used to create several skin-disease products, matching Ojer's model of one delivery technology feeding many products.

~$90MComparable

Foamix Pharmaceuticals

Israel · www.vynetherapeutics.com ↗

A specialty dermatology company built on a proprietary topical foam delivery platform that carries existing actives to the skin, the same platform-plus-reformulation model as Ojer's gel.

~$60MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 8

Open as list →

Inveready

inveready.com

3 rounds, led 1 · 2014–23 Spain

Dozen Investments

dozeninvestments.com

2 rounds, led 1 · 2020–23 Spain

Clave Capital

clave.capital

3 rounds · 2014–23 Spain

Sodena

www.sodena.com

2 rounds · 2014–19 Spain

Easo Ventures

easoventures.com

Seed 2023 Spain

Caja Navarra

Seed 2011 Spain

Fundación Caja Navarra

www.fundacioncajanavarra.es ↗

Investor Spain

Fundación Universitaria de Navarra (FUNA)

funa.es ↗

Investor Spain

Funding rounds 5

Date	Round	Amount	Lead
2023-03-24	Seed (estimated)	€2.3M	Lead not disclosed +4 more
2020-01	Seed	€1M	Dozen Investments
2019-05-31	Seed (estimated)	€640K	Lead not disclosed +4 more
2014-07-18	Seed	€600K	Inveready +2 more
2011-06-06	Seed	€500K	Lead not disclosed +1 more

News

No coverage on record yet.